Straumann, the Swiss dental implant manufacturer, reported first-half revenue of CHF 1.38 billion, a 2.3% increase year-over-year. Organic growth, excluding acquisitions and currency effects, reached 7.8%, down from 10.2% in the same period last year.
All regions contributed to growth, though at varying rates. Europe, the Middle East and Africa, Straumann’s largest market, saw organic revenue rise 8.2% to CHF 573 million. North America grew 8.1%, while Asia expanded 4.2%. Latin America posted the strongest performance with a 15.4% increase. The U.S. and China remained key focus areas, with patient visits in the U.S. described as stable despite cautious consumer sentiment. In China, Straumann continues to await the next price reform (VBP 2.0), which may begin in the second half of 2024 and take effect at the start of 2027.
Operating profit (EBIT) rose to CHF 351 million from CHF 330 million a year earlier, while net income increased to CHF 251 million from CHF 238 million. The adjusted core operating profit declined slightly to CHF 355 million, with the margin easing to 25.7% from 26.6% in the prior-year period. The core figure excludes certain one-off items.
Straumann’s management reaffirmed its full-year guidance, maintaining its outlook for organic revenue growth in the high single digits. The company had already raised its core EBIT margin forecast for 2026 by 140 to 170 basis points earlier in June.
The announcement of a CEO transition added a secondary headline. Christopher Norbye will take over as chief operating officer on December 1, 2026, succeeding Guillaume Daniellot, who will step down after nearly two decades with the company, including seven years as CEO.
